Biologically Focused Therapy of Treatment-Refractory MDS Patients

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

NCT03359460 ·Status: COMPLETED ·Phase: PHASE1

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

NCT04109482 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

NCT04263181 ·Status: ACTIVE_NOT_RECRUITING

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

NCT01928537 ·Status: COMPLETED ·Phase: PHASE3

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

NCT02002936 ·Status: COMPLETED ·Phase: PHASE1

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

NCT05925504 ·Status: RECRUITING ·Phase: PHASE2

Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

NCT01828346 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

NCT02093429 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

NCT02268383 ·Status: COMPLETED ·Phase: PHASE2

Phase I Study of Gimatecan in Patients With Myelodysplastic Syndromes

NCT00493571 ·Status: COMPLETED ·Phase: PHASE1

Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)

NCT01749514 ·Status: COMPLETED ·Phase: PHASE2

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

NCT00255346 ·Status: COMPLETED ·Phase: PHASE2

LBH589 in Refractory Myelodysplastic Syndromes (MDS)

NCT00594230 ·Status: TERMINATED ·Phase: PHASE2

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

NCT05568225 ·Status: TERMINATED ·Phase: PHASE2

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

NCT02014051 ·Status: COMPLETED ·Phase: PHASE1

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

NCT05181592 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

NCT00282399 ·Status: TERMINATED ·Phase: PHASE1

Decitabine in Treating Patients With Myelodysplastic Syndrome

NCT00003361 ·Status: COMPLETED ·Phase: PHASE2

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

NCT05835011 ·Status: TERMINATED ·Phase: PHASE2

Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT04402541 ·Status: COMPLETED ·Phase: PHASE1

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

NCT04539236 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

NCT02000154 ·Status: COMPLETED ·Phase: PHASE1

Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes

NCT00828802 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept

NCT07075406 ·Status: COMPLETED

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT00939159 ·Status: TERMINATED ·Phase: PHASE2